Copyright © Inderes 2011 - present. All rights reserved.

Gubra

390,60 DKK

-0,51 %

Mindre end 1K følgere

GUBRA

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

-0,51 %
-20,45 %
-24,52 %
-10,45 %
+14,01 %
-41,87 %
-
-
+255,09 %

Gubra er en medicinalvirksomhed. Virksomhedens aktiviteter er fokuseret på de tidlige stadier af lægemiddeludvikling. De udfører hovedsageligt forskning og udvikling inden for stofskifte- og fibrotiske sygdomme.Virksomhedens produktportefølje omfatter flere brands og lægemidler, og aktiviteterne foregår på globalt plan med den største tilstedeværelse i Nordamerika og Norden. Hovedkontoret ligger i Hørsholm, Danmark.

Læs mere
Markedsværdi
6,39 mia. DKK
Aktieomsætning
20,51 mio. DKK
Omsætning
265,74 mio.
EBIT %
-18,82 %
P/E
-
Udbytteafkast, %
15,67 %
Dækning
Disclaimer
Philip Coombes
Michael Friis
Michael Friis, Philip Coombes
Vis mere
Seneste analyse

Seneste analyse

Udgivelse: 01.12.2025

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
27.2
2026

Årsrapport '25

ViserAlle indholdstyper

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Gubra - Further validation of the streaMline platform, adding further long-term optionality
Analytikerkommentar af
Philip Coombes

Gubra - Further validation of the streaMline platform, adding further long-term optionality

Amylyx Pharmaceuticals has selected AMX0318, a long-acting drug discovered with Gubra, as a development candidate, triggering a USD 4m milestone and carrying >USD 50m in potential milestones plus royalties. While modest versus Gubra’s AbbVie partnership and UCN2, the progression further validates the streaMLine platform and its long-term optionality.

Gubra
Gubra - New partnership with Camurus to develop a long-acting treatment for hypoparathyroidism
Analytikerkommentar af
Philip Coombes

Gubra - New partnership with Camurus to develop a long-acting treatment for hypoparathyroidism

Gubra has entered into an exclusive collaboration and license agreement with Camurus to develop a long-acting treatment for hypoparathyroidism, combining Gubra’s parathyroid hormone (PTH) analogue (discovered via its AI-enabled streaMLine platform) with Camurus’ FluidCrystal® sustained-release technology. The aim is to reduce injection frequency and improve disease control versus current once-daily PTH therapies, addressing a clear unmet need in this rare endocrine disorder. 

Gubra
Gubra - Partner progresses obestiy asset into mid-stage, further validating differentiated obesity approach
Analytikerkommentar af
Philip Coombes, Michael Friis

Gubra - Partner progresses obestiy asset into mid-stage, further validating differentiated obesity approach

Gubra announced this morning that its partner, Boehringer Ingelheim, is advancing BI 3034701, a next-generation triple-agonist peptide for the treatment of obesity, into mid-stage clinical development following completion of the Phase I study. No data have been released, but the decision to progress the candidate follows a randomized, placebo-controlled Phase I trial in healthy volunteers and individuals with overweight or obesity, in which BI 3034701 demonstrated a favourable safety and tolerability profile together with promising early weight-loss effects.

Gubra
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.